Switching from Eculizumab to Ravulizumab for aHUS after Kidney Transplant
Author Information
Author(s): Busutti Marco, Maritati Federica, Borelli Greta, Bini Claudia, Corradetti Valeria, Cuna Vania, Abenavoli Chiara, Provenzano Michele, Ravaioli Matteo
Primary Institution: IRCCS Azienda Ospedaliero-Universitaria Di Bologna
Hypothesis
Is switching from eculizumab to ravulizumab effective and safe for maintaining aHUS remission after kidney transplant?
Conclusion
Switching from eculizumab to ravulizumab appears to be effective and safe for maintaining aHUS remission in kidney transplant recipients.
Supporting Evidence
- Both patients maintained stable graft function without signs of aHUS relapse after switching medications.
- The switch to ravulizumab was well tolerated with no reported adverse events.
- Quality of life improved significantly in both patients after the switch.
Takeaway
Doctors switched two patients from one medicine to another to help them stay healthy after a kidney transplant, and it worked well for both.
Methodology
Case reports of two patients who switched from eculizumab to ravulizumab for aHUS remission maintenance after kidney transplant.
Limitations
The study is based on a small case series.
Participant Demographics
Two young women with aHUS and end-stage kidney disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website